Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.
sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer.
Lau
Sin C
SC
Cancer Research UK, Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.
Rosa
Daniela D
DD
Jayson
Gordon
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000098:blood supply / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000378:metabolism / Q000627:therapeutic use*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2